Table 3.

Immunosuppressive maintenance therapy in ANCA-associated glomerulonephritis according to the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases (43).

Rituximab	Azathioprine	Mycophenolate mofetil	Methotrexate
500 mg twice at complete remission, and 500 mg at months 6, 12, and 18 (MAINRITSAN) OR 1,000 mg after remission induction and at months 4, 8, and 16 after the first infusion (RITAZERAM)	1.5–2 mg/kg/day at complete remission until 1 year after diagnosis, tapering by 25 mg every 3 months OR Extended protocol: 1.5–2 mg/kg/day for 18–24 months, then decrease dose to 1 mg/kg/day until 4 years after the diagnosis, then decrease by 25 mg every 3 months Glucocorticoids should also be continued at 5–7.5 mg/day (prednisolone-equivalent) for 2 years and then slowly reduced by 1 mg every 2 months	2,000 mg/day (divided doses) at complete remission for 2 years	Up to 25 mg/week if eGFR > 60 ml/min/1.73 m2

eGFR, estimated glomerular filtration rate.